CLDN4 and carcinoma: With the availability of alternative carcinoma markers, in particular the more recently available claudin-4 which demonstrated high sensitivity [5], it is important to review the diagnostic performance of the more established MOC31 immunostain as an option for specific clinical scenarios or with claudin-4 or other markers [6].